APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intramuscular Injection of Pain Medication

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Intramuscular Injection of Pain Medication Market Analysis and Forecast 2026-2032

23 December 2025203 pages

Choose your research edition.

Industry ResearchIntramuscular Injection of Pain Medication Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Intramuscular Injection of Pain Medication Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Intramuscular Injection of Pain Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intramuscular Injection of Pain Medication Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Intramuscular Injection of Pain Medication Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Intramuscular Injection of Pain Medication market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Intramuscular Injection of Pain Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Intramuscular Injection of Pain Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Intramuscular Injection of Pain Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Intramuscular Injection of Pain Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Intramuscular Injection of Pain Medication include Yangtze River Pharmaceutical Group (YRPG), Shijiazhuang Pharmaceutical Group, Sanofi, Humanwell Healthcare, Qilu Pharmaceutical, Novartis, Merck, Roche and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Intramuscular Injection of Pain Medication, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Intramuscular Injection of Pain Medication, also provides the revenue of main regions and countries. Of the upcoming market potential for Intramuscular Injection of Pain Medication, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Intramuscular Injection of Pain Medication revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Intramuscular Injection of Pain Medication market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Intramuscular Injection of Pain Medication revenue, projected growth trends, production technology, application and end-user industry.

Intramuscular Injection of Pain Medication Segment by Company

Yangtze River Pharmaceutical Group (YRPG)

Shijiazhuang Pharmaceutical Group

Sanofi

Humanwell Healthcare

Qilu Pharmaceutical

Novartis

Merck

Roche

Pfizer

China Resources Double Crane

Hengrui Medicine

Sinopharm Group

Fresenius Kabi

Northeast Pharmaceuticals

AstraZeneca

Hikma Pharmaceuticals

Grünenthal

Intramuscular Injection of Pain Medication Segment by Type

Opioid Analgesics (Opioids)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Local Anesthetics

Others

Intramuscular Injection of Pain Medication Segment by Application

Hospital

Clinic

Others

Intramuscular Injection of Pain Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intramuscular Injection of Pain Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intramuscular Injection of Pain Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intramuscular Injection of Pain Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Intramuscular Injection of Pain Medication in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Intramuscular Injection of Pain Medication company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Intramuscular Injection of Pain Medication revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Opioid Analgesics (Opioids) Major Player Table 3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Major Player Table 4. Local Anesthetics Major Player Table 5. Others Major Player Table 6. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Clinic Major Player Table 9. Others Major Player Table 10. Intramuscular Injection of Pain Medication Industry Trends Table 11. Intramuscular Injection of Pain Medication Industry Drivers Table 12. Intramuscular Injection of Pain Medication Industry Opportunities and Challenges Table 13. Intramuscular Injection of Pain Medication Industry Restraints Table 14. Global Intramuscular Injection of Pain Medication Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Intramuscular Injection of Pain Medication Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Intramuscular Injection of Pain Medication Market Share by Region (2021-2026) Table 17. Global Intramuscular Injection of Pain Medication Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Intramuscular Injection of Pain Medication Market Share by Region (2027-2032) Table 19. Global Intramuscular Injection of Pain Medication Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Intramuscular Injection of Pain Medication Revenue Market Share by Players (2021-2026) Table 21. Global Intramuscular Injection of Pain Medication Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Intramuscular Injection of Pain Medication Key Players Headquarters & Area Served Table 23. Global Intramuscular Injection of Pain Medication Players, Product Type & Application Table 24. Global Intramuscular Injection of Pain Medication Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Intramuscular Injection of Pain Medication by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Intramuscular Injection of Pain Medication Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Intramuscular Injection of Pain Medication Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Intramuscular Injection of Pain Medication Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Intramuscular Injection of Pain Medication Revenue Market Share by Type (2021-2026) Table 31. Global Intramuscular Injection of Pain Medication Revenue Market Share by Type (2027-2032) Table 32. Global Intramuscular Injection of Pain Medication Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Intramuscular Injection of Pain Medication Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Intramuscular Injection of Pain Medication Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Intramuscular Injection of Pain Medication Revenue Market Share by Application (2021-2026) Table 36. Global Intramuscular Injection of Pain Medication Revenue Market Share by Application (2027-2032) Table 37. Yangtze River Pharmaceutical Group (YRPG) Company Information Table 38. Yangtze River Pharmaceutical Group (YRPG) Business Overview Table 39. Yangtze River Pharmaceutical Group (YRPG) Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Yangtze River Pharmaceutical Group (YRPG) Intramuscular Injection of Pain Medication Product Portfolio Table 41. Yangtze River Pharmaceutical Group (YRPG) Recent Development Table 42. Shijiazhuang Pharmaceutical Group Company Information Table 43. Shijiazhuang Pharmaceutical Group Business Overview Table 44. Shijiazhuang Pharmaceutical Group Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Shijiazhuang Pharmaceutical Group Intramuscular Injection of Pain Medication Product Portfolio Table 46. Shijiazhuang Pharmaceutical Group Recent Development Table 47. Sanofi Company Information Table 48. Sanofi Business Overview Table 49. Sanofi Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Sanofi Intramuscular Injection of Pain Medication Product Portfolio Table 51. Sanofi Recent Development Table 52. Humanwell Healthcare Company Information Table 53. Humanwell Healthcare Business Overview Table 54. Humanwell Healthcare Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Humanwell Healthcare Intramuscular Injection of Pain Medication Product Portfolio Table 56. Humanwell Healthcare Recent Development Table 57. Qilu Pharmaceutical Company Information Table 58. Qilu Pharmaceutical Business Overview Table 59. Qilu Pharmaceutical Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Qilu Pharmaceutical Intramuscular Injection of Pain Medication Product Portfolio Table 61. Qilu Pharmaceutical Recent Development Table 62. Novartis Company Information Table 63. Novartis Business Overview Table 64. Novartis Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Novartis Intramuscular Injection of Pain Medication Product Portfolio Table 66. Novartis Recent Development Table 67. Merck Company Information Table 68. Merck Business Overview Table 69. Merck Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Merck Intramuscular Injection of Pain Medication Product Portfolio Table 71. Merck Recent Development Table 72. Roche Company Information Table 73. Roche Business Overview Table 74. Roche Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Roche Intramuscular Injection of Pain Medication Product Portfolio Table 76. Roche Recent Development Table 77. Pfizer Company Information Table 78. Pfizer Business Overview Table 79. Pfizer Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Pfizer Intramuscular Injection of Pain Medication Product Portfolio Table 81. Pfizer Recent Development Table 82. China Resources Double Crane Company Information Table 83. China Resources Double Crane Business Overview Table 84. China Resources Double Crane Intramuscular Injection of Pain Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. China Resources Double Crane Intramuscular Injection of Pain Medication Product Portfolio Table 86. China Resources Double Crane Recent Development Table 87. Hengrui Medicine Company Information Table 88. Hengrui Medicine Business Overview Table 89. Hengrui Medicine Intramuscular Injection of Pain Medication Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Hengrui Medicine Intramuscular Injection of Pain Medication Product Portfolio Table 91. Hengrui Medicine Recent Development Table 92. Sinopharm Group Company Information Table 93. Sinopharm Group Business Overview Table 94. Sinopharm Group Intramuscular Injection of Pain Medication Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Sinopharm Group Intramuscular Injection of Pain Medication Product Portfolio Table 96. Sinopharm Group Recent Development Table 97. Fresenius Kabi Company Information Table 98. Fresenius Kabi Business Overview Table 99. Fresenius Kabi Intramuscular Injection of Pain Medication Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Fresenius Kabi Intramuscular Injection of Pain Medication Product Portfolio Table 101. Fresenius Kabi Recent Development Table 102. Northeast Pharmaceuticals Company Information Table 103. Northeast Pharmaceuticals Business Overview Table 104. Northeast Pharmaceuticals Intramuscular Injection of Pain Medication Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Northeast Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio Table 106. Northeast Pharmaceuticals Recent Development Table 107. AstraZeneca Company Information Table 108. AstraZeneca Business Overview Table 109. AstraZeneca Intramuscular Injection of Pain Medication Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. AstraZeneca Intramuscular Injection of Pain Medication Product Portfolio Table 111. AstraZeneca Recent Development Table 112. Hikma Pharmaceuticals Company Information Table 113. Hikma Pharmaceuticals Business Overview Table 114. Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio Table 116. Hikma Pharmaceuticals Recent Development Table 117. Grünenthal Company Information Table 118. Grünenthal Business Overview Table 119. Grünenthal Intramuscular Injection of Pain Medication Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Grünenthal Intramuscular Injection of Pain Medication Product Portfolio Table 121. Grünenthal Recent Development Table 122. North America Intramuscular Injection of Pain Medication Revenue by Type (2021-2026) & (US$ Million) Table 123. North America Intramuscular Injection of Pain Medication Revenue by Type (2027-2032) & (US$ Million) Table 124. North America Intramuscular Injection of Pain Medication Revenue by Application (2021-2026) & (US$ Million) Table 125. North America Intramuscular Injection of Pain Medication Revenue by Application (2027-2032) & (US$ Million) Table 126. North America Intramuscular Injection of Pain Medication Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. North America Intramuscular Injection of Pain Medication Revenue by Country (2021-2026) & (US$ Million) Table 128. North America Intramuscular Injection of Pain Medication Revenue by Country (US$ Million) & (2027-2032) Table 129. Europe Intramuscular Injection of Pain Medication Revenue by Type (2021-2026) & (US$ Million) Table 130. Europe Intramuscular Injection of Pain Medication Revenue by Type (2027-2032) & (US$ Million) Table 131. Europe Intramuscular Injection of Pain Medication Revenue by Application (2021-2026) & (US$ Million) Table 132. Europe Intramuscular Injection of Pain Medication Revenue by Application (2027-2032) & (US$ Million) Table 133. Europe Intramuscular Injection of Pain Medication Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Europe Intramuscular Injection of Pain Medication Revenue by Country (2021-2026) & (US$ Million) Table 135. Europe Intramuscular Injection of Pain Medication Revenue by Country (US$ Million) & (2027-2032) Table 136. China Intramuscular Injection of Pain Medication Revenue by Type (2021-2026) & (US$ Million) Table 137. China Intramuscular Injection of Pain Medication Revenue by Type (2027-2032) & (US$ Million) Table 138. China Intramuscular Injection of Pain Medication Revenue by Application (2021-2026) & (US$ Million) Table 139. China Intramuscular Injection of Pain Medication Revenue by Application (2027-2032) & (US$ Million) Table 140. Asia Intramuscular Injection of Pain Medication Revenue by Type (2021-2026) & (US$ Million) Table 141. Asia Intramuscular Injection of Pain Medication Revenue by Type (2027-2032) & (US$ Million) Table 142. Asia Intramuscular Injection of Pain Medication Revenue by Application (2021-2026) & (US$ Million) Table 143. Asia Intramuscular Injection of Pain Medication Revenue by Application (2027-2032) & (US$ Million) Table 144. Asia Intramuscular Injection of Pain Medication Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Asia Intramuscular Injection of Pain Medication Revenue by Region (US$ Million) & (2021-2026) Table 146. Asia Intramuscular Injection of Pain Medication Revenue by Region (US$ Million) & (2027-2032) Table 147. SAMEA Intramuscular Injection of Pain Medication Revenue by Type (2021-2026) & (US$ Million) Table 148. SAMEA Intramuscular Injection of Pain Medication Revenue by Type (2027-2032) & (US$ Million) Table 149. SAMEA Intramuscular Injection of Pain Medication Revenue by Application (2021-2026) & (US$ Million) Table 150. SAMEA Intramuscular Injection of Pain Medication Revenue by Application (2027-2032) & (US$ Million) Table 151. SAMEA Intramuscular Injection of Pain Medication Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. SAMEA Intramuscular Injection of Pain Medication Revenue by Country (2021-2026) & (US$ Million) Table 153. SAMEA Intramuscular Injection of Pain Medication Revenue by Country (US$ Million) & (2027-2032) Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Intramuscular Injection of Pain Medication Image Figure 2. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intramuscular Injection of Pain Medication Market Size Share 2021 VS 2025 VS 2032 Figure 4. Opioid Analgesics (Opioids) Image Figure 5. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Image Figure 6. Local Anesthetics Image Figure 7. Others Image Figure 8. Global Intramuscular Injection of Pain Medication Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Intramuscular Injection of Pain Medication Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Intramuscular Injection of Pain Medication Market Size (US$ Million) & (2021-2032) Figure 14. Global Intramuscular Injection of Pain Medication Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Intramuscular Injection of Pain Medication Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Intramuscular Injection of Pain Medication Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Intramuscular Injection of Pain Medication Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Intramuscular Injection of Pain Medication Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Intramuscular Injection of Pain Medication Revenue Market Share by Type (2021-2032) Figure 21. Global Intramuscular Injection of Pain Medication Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Intramuscular Injection of Pain Medication Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Intramuscular Injection of Pain Medication Revenue Market Share by Application (2021-2032) Figure 24. North America Intramuscular Injection of Pain Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032) Figure 26. North America Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032) Figure 27. North America Intramuscular Injection of Pain Medication Revenue Share by Country (2021-2032) Figure 28. United States Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Intramuscular Injection of Pain Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032) Figure 33. Europe Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032) Figure 34. Europe Intramuscular Injection of Pain Medication Revenue Share by Country (2021-2032) Figure 35. Germany Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Intramuscular Injection of Pain Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032) Figure 45. China Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032) Figure 46. Asia Intramuscular Injection of Pain Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032) Figure 48. Asia Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032) Figure 49. Asia Intramuscular Injection of Pain Medication Revenue Share by Region (2021-2032) Figure 50. Japan Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Intramuscular Injection of Pain Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032) Figure 58. SAMEA Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032) Figure 59. SAMEA Intramuscular Injection of Pain Medication Revenue Share by Country (2021-2032) Figure 60. Brazil Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Intramuscular Injection of Pain Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Opioid Analgesics (Opioids)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Local Anesthetics
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Yangtze River Pharmaceutical Group (YRPG)
  • Shijiazhuang Pharmaceutical Group
  • Sanofi
  • Humanwell Healthcare
  • Qilu Pharmaceutical
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • China Resources Double Crane
  • Hengrui Medicine
  • Sinopharm Group
  • Fresenius Kabi
  • Northeast Pharmaceuticals
  • AstraZeneca
  • Hikma Pharmaceuticals
  • Grünenthal

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Intramuscular Injection of Pain Medication Market by Type
  3. 1.2.1 Global Intramuscular Injection of Pain Medication Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Opioid Analgesics (Opioids)
  5. 1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  6. 1.2.4 Local Anesthetics
  7. 1.2.5 Others
  8. 1.3 Intramuscular Injection of Pain Medication Market by Application
  9. 1.3.1 Global Intramuscular Injection of Pain Medication Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Intramuscular Injection of Pain Medication Market Dynamics
  1. 2.1 Intramuscular Injection of Pain Medication Industry Trends
  2. 2.2 Intramuscular Injection of Pain Medication Industry Drivers
  3. 2.3 Intramuscular Injection of Pain Medication Industry Opportunities and Challenges
  4. 2.4 Intramuscular Injection of Pain Medication Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Intramuscular Injection of Pain Medication Market Perspective (2021-2032)
  2. 3.2 Global Intramuscular Injection of Pain Medication Growth Trends by Region
  3. 3.2.1 Global Intramuscular Injection of Pain Medication Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Intramuscular Injection of Pain Medication Market Size by Region (2021-2026)
  5. 3.2.3 Global Intramuscular Injection of Pain Medication Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Intramuscular Injection of Pain Medication Revenue by Players
  2. 4.1.1 Global Intramuscular Injection of Pain Medication Revenue by Players (2021-2026)
  3. 4.1.2 Global Intramuscular Injection of Pain Medication Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Intramuscular Injection of Pain Medication Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Intramuscular Injection of Pain Medication Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Intramuscular Injection of Pain Medication Key Players Headquarters & Area Served
  7. 4.4 Global Intramuscular Injection of Pain Medication Players, Product Type & Application
  8. 4.5 Global Intramuscular Injection of Pain Medication Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Intramuscular Injection of Pain Medication Market CR5 and HHI
  11. 4.6.3 2025 Intramuscular Injection of Pain Medication Tier 1, Tier 2, and Tier 3
5 Intramuscular Injection of Pain Medication Market Size by Type
  1. 5.1 Global Intramuscular Injection of Pain Medication Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Intramuscular Injection of Pain Medication Revenue by Type (2021-2032)
  3. 5.3 Global Intramuscular Injection of Pain Medication Revenue Market Share by Type (2021-2032)
6 Intramuscular Injection of Pain Medication Market Size by Application
  1. 6.1 Global Intramuscular Injection of Pain Medication Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Intramuscular Injection of Pain Medication Revenue by Application (2021-2032)
  3. 6.3 Global Intramuscular Injection of Pain Medication Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Yangtze River Pharmaceutical Group (YRPG)
  2. 7.1.1 Yangtze River Pharmaceutical Group (YRPG) Company Information
  3. 7.1.2 Yangtze River Pharmaceutical Group (YRPG) Business Overview
  4. 7.1.3 Yangtze River Pharmaceutical Group (YRPG) Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Yangtze River Pharmaceutical Group (YRPG) Intramuscular Injection of Pain Medication Product Portfolio
  6. 7.1.5 Yangtze River Pharmaceutical Group (YRPG) Recent Developments
  7. 7.2 Shijiazhuang Pharmaceutical Group
  8. 7.2.1 Shijiazhuang Pharmaceutical Group Company Information
  9. 7.2.2 Shijiazhuang Pharmaceutical Group Business Overview
  10. 7.2.3 Shijiazhuang Pharmaceutical Group Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Shijiazhuang Pharmaceutical Group Intramuscular Injection of Pain Medication Product Portfolio
  12. 7.2.5 Shijiazhuang Pharmaceutical Group Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Intramuscular Injection of Pain Medication Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Humanwell Healthcare
  20. 7.4.1 Humanwell Healthcare Company Information
  21. 7.4.2 Humanwell Healthcare Business Overview
  22. 7.4.3 Humanwell Healthcare Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Humanwell Healthcare Intramuscular Injection of Pain Medication Product Portfolio
  24. 7.4.5 Humanwell Healthcare Recent Developments
  25. 7.5 Qilu Pharmaceutical
  26. 7.5.1 Qilu Pharmaceutical Company Information
  27. 7.5.2 Qilu Pharmaceutical Business Overview
  28. 7.5.3 Qilu Pharmaceutical Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Qilu Pharmaceutical Intramuscular Injection of Pain Medication Product Portfolio
  30. 7.5.5 Qilu Pharmaceutical Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Intramuscular Injection of Pain Medication Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck Intramuscular Injection of Pain Medication Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Roche
  44. 7.8.1 Roche Company Information
  45. 7.8.2 Roche Business Overview
  46. 7.8.3 Roche Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Roche Intramuscular Injection of Pain Medication Product Portfolio
  48. 7.8.5 Roche Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Intramuscular Injection of Pain Medication Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 China Resources Double Crane
  56. 7.10.1 China Resources Double Crane Company Information
  57. 7.10.2 China Resources Double Crane Business Overview
  58. 7.10.3 China Resources Double Crane Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  59. 7.10.4 China Resources Double Crane Intramuscular Injection of Pain Medication Product Portfolio
  60. 7.10.5 China Resources Double Crane Recent Developments
  61. 7.11 Hengrui Medicine
  62. 7.11.1 Hengrui Medicine Company Information
  63. 7.11.2 Hengrui Medicine Business Overview
  64. 7.11.3 Hengrui Medicine Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Hengrui Medicine Intramuscular Injection of Pain Medication Product Portfolio
  66. 7.11.5 Hengrui Medicine Recent Developments
  67. 7.12 Sinopharm Group
  68. 7.12.1 Sinopharm Group Company Information
  69. 7.12.2 Sinopharm Group Business Overview
  70. 7.12.3 Sinopharm Group Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sinopharm Group Intramuscular Injection of Pain Medication Product Portfolio
  72. 7.12.5 Sinopharm Group Recent Developments
  73. 7.13 Fresenius Kabi
  74. 7.13.1 Fresenius Kabi Company Information
  75. 7.13.2 Fresenius Kabi Business Overview
  76. 7.13.3 Fresenius Kabi Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Fresenius Kabi Intramuscular Injection of Pain Medication Product Portfolio
  78. 7.13.5 Fresenius Kabi Recent Developments
  79. 7.14 Northeast Pharmaceuticals
  80. 7.14.1 Northeast Pharmaceuticals Company Information
  81. 7.14.2 Northeast Pharmaceuticals Business Overview
  82. 7.14.3 Northeast Pharmaceuticals Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Northeast Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio
  84. 7.14.5 Northeast Pharmaceuticals Recent Developments
  85. 7.15 AstraZeneca
  86. 7.15.1 AstraZeneca Company Information
  87. 7.15.2 AstraZeneca Business Overview
  88. 7.15.3 AstraZeneca Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  89. 7.15.4 AstraZeneca Intramuscular Injection of Pain Medication Product Portfolio
  90. 7.15.5 AstraZeneca Recent Developments
  91. 7.16 Hikma Pharmaceuticals
  92. 7.16.1 Hikma Pharmaceuticals Company Information
  93. 7.16.2 Hikma Pharmaceuticals Business Overview
  94. 7.16.3 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio
  96. 7.16.5 Hikma Pharmaceuticals Recent Developments
  97. 7.17 Grünenthal
  98. 7.17.1 Grünenthal Company Information
  99. 7.17.2 Grünenthal Business Overview
  100. 7.17.3 Grünenthal Intramuscular Injection of Pain Medication Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Grünenthal Intramuscular Injection of Pain Medication Product Portfolio
  102. 7.17.5 Grünenthal Recent Developments
8 North America
  1. 8.1 North America Intramuscular Injection of Pain Medication Revenue (2021-2032)
  2. 8.2 North America Intramuscular Injection of Pain Medication Revenue by Type (2021-2032)
  3. 8.2.1 North America Intramuscular Injection of Pain Medication Revenue by Type (2021-2026)
  4. 8.2.2 North America Intramuscular Injection of Pain Medication Revenue by Type (2027-2032)
  5. 8.3 North America Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032)
  6. 8.4 North America Intramuscular Injection of Pain Medication Revenue by Application (2021-2032)
  7. 8.4.1 North America Intramuscular Injection of Pain Medication Revenue by Application (2021-2026)
  8. 8.4.2 North America Intramuscular Injection of Pain Medication Revenue by Application (2027-2032)
  9. 8.5 North America Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032)
  10. 8.6 North America Intramuscular Injection of Pain Medication Revenue by Country
  11. 8.6.1 North America Intramuscular Injection of Pain Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Intramuscular Injection of Pain Medication Revenue by Country (2021-2026)
  13. 8.6.3 North America Intramuscular Injection of Pain Medication Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Intramuscular Injection of Pain Medication Revenue (2021-2032)
  2. 9.2 Europe Intramuscular Injection of Pain Medication Revenue by Type (2021-2032)
  3. 9.2.1 Europe Intramuscular Injection of Pain Medication Revenue by Type (2021-2026)
  4. 9.2.2 Europe Intramuscular Injection of Pain Medication Revenue by Type (2027-2032)
  5. 9.3 Europe Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032)
  6. 9.4 Europe Intramuscular Injection of Pain Medication Revenue by Application (2021-2032)
  7. 9.4.1 Europe Intramuscular Injection of Pain Medication Revenue by Application (2021-2026)
  8. 9.4.2 Europe Intramuscular Injection of Pain Medication Revenue by Application (2027-2032)
  9. 9.5 Europe Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032)
  10. 9.6 Europe Intramuscular Injection of Pain Medication Revenue by Country
  11. 9.6.1 Europe Intramuscular Injection of Pain Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Intramuscular Injection of Pain Medication Revenue by Country (2021-2026)
  13. 9.6.3 Europe Intramuscular Injection of Pain Medication Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Intramuscular Injection of Pain Medication Revenue (2021-2032)
  2. 10.2 China Intramuscular Injection of Pain Medication Revenue by Type (2021-2032)
  3. 10.2.1 China Intramuscular Injection of Pain Medication Revenue by Type (2021-2026)
  4. 10.2.2 China Intramuscular Injection of Pain Medication Revenue by Type (2027-2032)
  5. 10.3 China Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032)
  6. 10.4 China Intramuscular Injection of Pain Medication Revenue by Application (2021-2032)
  7. 10.4.1 China Intramuscular Injection of Pain Medication Revenue by Application (2021-2026)
  8. 10.4.2 China Intramuscular Injection of Pain Medication Revenue by Application (2027-2032)
  9. 10.5 China Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Intramuscular Injection of Pain Medication Revenue (2021-2032)
  2. 11.2 Asia Intramuscular Injection of Pain Medication Revenue by Type (2021-2032)
  3. 11.2.1 Asia Intramuscular Injection of Pain Medication Revenue by Type (2021-2026)
  4. 11.2.2 Asia Intramuscular Injection of Pain Medication Revenue by Type (2027-2032)
  5. 11.3 Asia Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032)
  6. 11.4 Asia Intramuscular Injection of Pain Medication Revenue by Application (2021-2032)
  7. 11.4.1 Asia Intramuscular Injection of Pain Medication Revenue by Application (2021-2026)
  8. 11.4.2 Asia Intramuscular Injection of Pain Medication Revenue by Application (2027-2032)
  9. 11.5 Asia Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032)
  10. 11.6 Asia Intramuscular Injection of Pain Medication Revenue by Country
  11. 11.6.1 Asia Intramuscular Injection of Pain Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Intramuscular Injection of Pain Medication Revenue by Country (2021-2026)
  13. 11.6.3 Asia Intramuscular Injection of Pain Medication Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Intramuscular Injection of Pain Medication Revenue (2021-2032)
  2. 12.2 SAMEA Intramuscular Injection of Pain Medication Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Intramuscular Injection of Pain Medication Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Intramuscular Injection of Pain Medication Revenue by Type (2027-2032)
  5. 12.3 SAMEA Intramuscular Injection of Pain Medication Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Intramuscular Injection of Pain Medication Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Intramuscular Injection of Pain Medication Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Intramuscular Injection of Pain Medication Revenue by Application (2027-2032)
  9. 12.5 SAMEA Intramuscular Injection of Pain Medication Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Intramuscular Injection of Pain Medication Revenue by Country
  11. 12.6.1 SAMEA Intramuscular Injection of Pain Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Intramuscular Injection of Pain Medication Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Intramuscular Injection of Pain Medication Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst